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ABSTRAK
Latar belakang: retinopati diabetik (RD) tipe proliferatif merupakan bentuk lanjut RD yang selanjutnya dapat 
menyebabkan kebutaan. Kadar produk akhir glikasi/advanced glycation end products (AGEs) dan D-dimer cairan 
vitreus dapat menggambarkan perubahan patologi pada retina, tetapi hanya ada sedikit penelitian yang menilai 
korelasi antara kedua parameter tersebut dengan kadar HbA1c dalam darah. Tujuan penelitian ini menemukan 
hubungan antara kadar HbA1c darah dengan kadar AGEs dan D-dimer cairan vitreus pada pasien dengan RD 
tipe proliferatif. Metode: penelitian bersifat analitik potong lintang pada pasien dengan RD tipe proliferatif yang 
menjalani vitrektomi. Pasien dibagi dalam 2 kelompok yaitu hiperglikemi tidak terkendali (HbA1c > 7%) dan 
terkendali (HbA1c < 7%). Kadar AGEs dan D-dimer cairan vitreus diukur dan kadarnya dibandingkan antara 
pasien hiperglikemi tidak terkendali dan terkendali. Uji korelasi statistik juga dilakukan antara kadar HbA1c darah 
dengan kadar AGEs dan D-dimer cairan vitreus. Hasil: pasien berjumlah 47, dengan 32 (68.1%) pasien adalah 
wanita. Nilai median kadar AGEs cairan vitreus 11.0 (3.0 – 48.0) µg/mL, dan nilai median kadar D-dimer cairan 
vitreus 5,446.0 (44.0 – 37,394.0 ) ng/mL. Nilai median kadar AGEs cairan vitreus lebih tinggi bermakna pada 
pasien dengan hiperglikemia tidak terkendali dibandingkan dengan hiperglikemia terkendali (14.0 vs. 4.0 mg/mL; 
p<0.001). Terdapat korelasi positif bermakna dengan kekuatan sedang antara kadar HbA1c darah dan kadar AGEs 
cairan vitreus (r = 0.524; r2 = 0.130; p=0.0001). Kadar HbA1c darah dapat digunakan untuk memperkirakan kadar 
AGEs cairan vitreus dengan menggunakan rumus: kadar AGEs cairan vitreus = -1.442+(1.740xHbA1c darah). 
Kadar D-dimer cairan vitreus pasien dengan hiperglikemia tidak terkendali tidak berbeda bermakna dengan pasien 
hiperglikemia terkendali (median 4607.5 vs. 5701.6 ng/mL; p = 0.458). Terdapat korelasi positif bermakna tetapi 
dengan kekuatan lemah antara kadar HbA1c darah dengan kadar D-dimer cairan vitreus (r = 0.342; p = 0.019). 
Kadar AGEs cairan vitreus memiliki korelasi positif bermakna dengan kekuatan lemah dibandingkan dengan 
kadar D-dimer cairan vitreus (r = 0.292; p = 0.046). Kesimpulan: nilai median kadar AGEs cairan vitreus lebih 
tinggi bermakna pada pasien RD proliferatif dengan hiperglikemia tidak terkendali dibandingkan hiperglikemia 
terkendali. Kadar HbA1c darah dapat digunakan untuk memperkirakan kadar AGEs cairan vitreus pada pasien 
RD proliferatif dengan menggunakan rumus: kadar AGEs cairan vitreus = -1.442+ (1.740x HbA1c darah). Kadar 
HbA1c darah pada pasien RD proliferatif tidak dapat digunakan untuk memperkirakan kadar D-dimer cairan vitreus.
Kata kunci: produk akhir glikasi cairan vitreus, D-dimer cairan vitreus, retinopati diabetik proliferatif, 
HbA1c darah.
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INTRODUCTION
Diabetic retinopathy (DR) is one of the major 
microvascular complications of diabetes mellitus, 
which is caused by a retinal perfusion disorder 
due to chronic hyperglycemia. Proliferative 
DR is an advanced form of DR, which is 
characterized by neovascularization originating 
from the retina and/or optic disk.1,2 A previous 
study in our hospital has shown that patients with 
proliferative DR have increased vitreous vascular 
endothelial growth factor (VEGF), supporting 
its role in the pathogenesis of proliferative DR.3 
Various mechanisms are also involved in the 
pathogenesis of DR, such as activation of protein 
kinase C, stimulation of the polyol pathway and 
enhanced reactive oxygen species generation, 
activation of fructose-6-phosphate pathway, and 
increased production of advanced glycation end 
products (AGEs).4,5
In particular, high levels of AGEs may 
cause capillary membrane thickening and 
endothelial dysfunction that can stimulate 
coagulation system.6,7 AGEs accumulation may 
also stimulate glycation process in the platelet 
membrane protein and cause modification of the 
phospholipid structure of platelet’s membrane 
and increased platelet aggregation and adhesion 
leading to increased coagulation activation.8.9 
A pro-coagulant state is indeed observed in 
diabetes. Factors involved in coagulation system 
activation such as fibrinogen, factors VII, IX, etc. 
are usually elevated in diabetes.10
Elevated AGEs levels are found not only in 
serum but also in the vitreous.11 The production 
of AGEs occurs to a much greater degree in 
patients with uncontrolled hyperglycemia. In 
diabetic patients, AGEs levels may increase to 
20 folds in the vitreous humor.12 It is suggested 
that vitreous AGEs influence the transition from 
the non-proliferative to proliferative DR.13 AGEs 
ABSTRACT
Background: proliferative diabetic retinopathy (DR) is an advanced form of DR that eventually could lead to 
blindness. Levels of vitreous advanced glycation end products (AGEs) and D-dimer may reflect the pathological 
changes in the retina, but only few studies have assessed their correlation with blood hemoglobin A1C (HbA1c) 
levels. This study aimed to find the correlation between blood HbA1c levels with vitreous AGEs and D-dimer levels 
in patients with proliferative DR. Methods: an analytical cross-sectional study was performed in subjects with 
proliferative DR who underwent vitrectomy. Subjects were divided into 2 subgroups, i.e. uncontrolled (HbA1c >7%) 
and controlled (HbA1c <7%) groups. Vitreous AGEs and D-dimer levels were assessed; the levels were compared 
between uncontrolled and controlled hyperglycemic patients. Statistic correlation tests were also performed for 
evaluating blood HbA1c, vitreous AGEs, and D-dimer levels. Results: a total of 47 patients were enrolled in this 
study and 32 (68.1%) of them were women. Median vitreous AGEs level was 11.0 (3.0 – 48.0) µg/mL; whereas 
median vitreous D-dimers level was 5,446.0 (44.0 – 37,394.0 ) ng/mL. The median vitreous AGEs levels was 
significantly higher in patients with uncontrolled vs. controlled hyperglycemia (14.0 vs. 4.0 mg/mL; p<0.001). 
There was a significant positive correlation with moderate strength between blood HbA1c level and vitreous 
AGEs level (r=0.524; r2=0.130; p=0.0001). Blood HbA1c level could be used to predict vitreous AGEs level by 
using the following calculation: vitreous AGEs = -1.442+ (1.740xblood HbA1c). Vitreous D-dimer levels were not 
significantly different between uncontrolled and controlled hyperglycemia (median 4607.5 vs. 5701.6 ng/mL; p = 
0.458). There was a positive significant correlation between blood HbA1c and vitreous D-dimer levels (r = 0.342; p 
= 0.019); however the correlation was weak. Vitreous AGEs level had a positive significant correlation with vitreous 
D-dimer levels (r = 0.292; p = 0.046) and the correlation strength was also weak. Conclusion: median vitreous 
AGEs levels were significantly higher in proliferative DR patients with uncontrolled than those with controlled 
hyperglycemia. Blood HbA1c level can be used to assess vitreous AGEs level in patients with proliferative DR by 
using the following calculation: vitreous AGEs = -1.442+(1.740 x HbA1c). However, the blood HbA1c level can 
not be used to predict vitreous D-dimer level in patients with proliferative DR.
Keywords: vitreous advanced glycation end products, vitreous D-dimer, proliferative diabetic retinopathy, 
blood HbA1c.
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accumulation in the vitreous humor may cause 
chronic inflammation, neurodegeneration and 
retinal microvascularization dysfunction, which 
eventually impair vitreous permeability.14
D-dimer level has been used as a biomarker 
of hypercoagulability and fibrinolytic activity 
since it is a product of fibrin degradation.15 Study 
assessing D-dimer from vitreous humor is scarce, 
but it is suggested that high level of vitreous 
D-dimer may indicate a substantial damage of 
the blood-retinal barrier because it has large 
molecular size (molecular weight of 180 kDa) 
to penetrate into the vitreous body.16 Therefore, 
it is an important biomarker to indicate a more 
advanced stage of DR.
Currently, there is no method to predict 
vitreous AGEs levels or fibrinolytic activity 
from blood biomarkers. This study aimed to find 
the correlations between blood HbA1c levels, 
vitreous AGEs and vitreous D-dimers levels in 
patients with proliferative diabetic retinopathy.
METHODS
This was an analytical, cross-sectional study, 
which was conducted at the Department of Clinical 
Pathology, Cipto Mangunkusumo Hospital (CM 
Hospital) Jakarta, between January and June 2017. 
Subjects were proliferative DR patients recruited 
from Department of Ophthalmology, CM Hospital 
who were enrolled in the previous study3 and 
underwent vitrectomy. Vitreous specimens were 
stored at -80oC in the Laboratory of Clinical 
Pathology Department, CM Hospital.
Patients’ demography, clinical data and 
HbA1c levels were retrieved from medical 
records. Patients with HbA1c levels of <7% 
was designated as controlled hyperglycemia, 
whereas HbA1c of >7% was categorized in the 
uncontrolled hyperglycemia group.  Ethical 
approval was issued by the Ethical Committee, 
Faculty of Medicine, Universitas Indonesia by 
letter No. 487/UN2.F1/ETIK/2017.
Measurement of Intravitreal AGEs and 
D-dimer
Intravitreal AGEs levels were measured using 
enzyme-linked immunosorbent assay (ELISA) 
method with a commercial kit (OxiSelectTM 
Advanced Glycation End Product Competitive 
ELISA kit, Cell Biolabs Inc., USA). The result 
was expressed as µg/mL.  Intravitreal D-dimer 
levels were measured using enzyme-linked 
fluorescence assay (ELFA) method with a 
commercial kit (VIDAS® D-Dimer Exclusion 
II ASSAY, Bio Mérieux, France) and the results 
were expressed as ng/mL. The reference value 
for plasma D-dimer was <300 ng/mL.
Statistical Analyses
Patients’ demography and clinical data were 
presented descriptively. Vitreous AGEs and 
D-dimer levels were expressed as median and 
range due to their skewed distribution. Median 
differences between groups were analyzed using 
Mann-Whitney U test. A p value of less than 0.05 
was considered significant. Correlation tests were 
performed using Spearman’s rho correlation 
coefficient for skewed data. Statistical analyses 
were done using a statistical software SPSS 
version 17.0 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
A total of 47 patients were enrolled in this 
study and 32 (68.1%) of them were women. Mean 
age of the patients was 53.0 (SD 8.03) years old. 
Most patients had uncontrolled hyperglycemia 
(HbA1c > 7%) and had been diagnosed for less 
than 15 years (Table 1). 
Table 1. Subject characteristics (n=47)
Variables Median (range) n (%)
Gender
 - Male 15 (31.9)
 - Female 32 (68.1)
Glycemic control (HbA1c) 8.4 (5.4–13.5)
 - Controlled  
(HbA1c <7%) 11 (23.4)
 - Uncontrolled (HbA1c 
>7%) 36 (76.6)
Duration of diabetes 10 (1–35)
 - <15 years 33 (70.2)
 - >15 years 14 (29.8)
Vitreous AGEs and Vitreous D-dimer Levels
Median vitreous AGEs level was 11.0 (3.0 
– 48.0) µg/ mL, whereas the median vitreous 
D-dimer level was 5,446.0 (44.0 – 37,394.0) ng/
mL. Thirty-four (72.3%) patients had D-dimer 
level of  >300 ng/mL. 
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Correlation Between Blood HbA1c and 
Vitreous AGEs and Vitreous D-dimer Levels
Vitreous AGEs levels were significantly 
higher in patients with uncontrolled (HbA1c 
>7%) than controlled hyperglycemia (HbA1c 
<7%). The median was 14.0 vs. 4.0 mg/mL 
(p<0.001) for uncontrolled and controlled 
hyperglycemia, respectively (Figure 1). There 
was a significant positive correlation with 
moderate strength between blood HbA1c level 
and vitreous AGEs level (r=0.524; r2=0.130; 
p=0.0001). Blood HbA1c level could be used 
to predict vitreous AGEs level by the following 
calculation: 
Vitreous AGEs = -1.442 + (1.740 x HbA1c)
 Vitreous D-dimer levels were not significanly 
different between patients with uncontrolled and 
controlled hyperglycemia (median 4607.5 vs. 
5701.6 ng/mL; p=0.458) (Figure 2). There was 
a significant positive correlation with weak 
strength between HbA1c and vitreous D-dimer 
levels (r=0.342; p=0.019).
Vitreous AGEs was weakly correlated with 
vitreous D-dimer levels (r=0.292; p=0.046). 
Patients with vitreous D-dimer of more than 300 
ng/mL tended to have higher vitreous AGEs level 
than those with D-dimer of ≤300 ng/mL (12 vs. 
10 µg/mL; p=0.073).
DISCUSSION
This study is the first to evaluate the 
correlation among intravitreal AGEs, D-Dimer 
levels and blood HbA1c in Indonesian patients 
with proliferative DR. To our knowledge, this 
study also provided first data on vitreous AGEs 
and D-dimer levels comparing controlled and 
uncontrolled hyperglycemic DR patients. Female 
patients were predominant in this study, which 
is similar to another study about prevalence and 
risk factors for DR in Malay ethnic, which was 
conducted in Singapore (60-70%).21 The mean 
age of patients was also comparable with other 
Asian populations with DR.22
Our study has shown that high HbA1c was 
moderately associated with higher vitreous AGEs 
levels. This supports the theory that uncontrolled 
hyperglycemia has an important role in the 
pathogenesis of proliferative DR.13 Moreover, it 
can be said that we are able to predict vitreous 
AGEs levels based on HbA1c levels obtained 
from a blood sample taken from  the patients. 
This finding implies that HbA1c levels can 
be used to monitor disease progression in an 
individual patient.
High vitreous D-dimer levels in this study 
suggest that there was increased fibrinolytic 
activity in proliferative DR patients. A previous 
study has reported increased components of the 
fibrinolytic system, including D-dimer, in the 
vitreous body of vitreoretinal disorders. The mean 
vitreous D-dimer level was 1.64 µg/mL (1,640 
ng/mL) in patients with proliferative vitreoretinal 
disorder.16 The high vitreous D-dimer levels 
might be surprising since in another study, blood 
D-dimer levels in diabetic patients with DR was 
Figure 1. Vitreous AGEs levels between patients with 
uncontrolled (HbA1c >7%) and controlled (HbA1c <7%) 
hyperglycemia
Figure 2. Vitreous D-dimer levels between patients with 
uncontrolled (HbA1c >7%) and controlled (HbA1c <7%) 
hyperglycemia
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similar with diabetic patients without DR (0.2 vs. 
0.2 µg/mL; p = 0.960). The breakdown of the 
blood-retinal barrier is thought to be responsible 
for increased vitreous D-dimer levels and also 
other components of the fibrinolytic system.16
The wide range and skewed distribution 
of vitreous D-dimer levels may affect the 
statistical correlation test. The regression test 
was performed based on an assumption that 
numerical data have linear distribution, but we 
observed that high vitreous D-dimer levels could 
be found in patients with normal HbA1c levels. 
Other factors are involved in the pathogenesis 
of coagulation and fibrinolytic activities and 
these may influence the D-dimer levels in the 
vitreous humor.
This study has a limitation that it was not 
designed prospectively to provide evidences that 
uncontrolled hyperglycemia causes increased 
vitreous AGEs levels or fibrinolytic activity. 
Prospective studies may not be suitable due to 
ethical problem to obtain vitreous specimens 
from asymptomatic DR subjects. However, this 
study may suggest that it is important to control 
hyperglycemia to prevent the increase of vitreous 
AGEs level. On the other hand, abnormalities 
of coagulation and fibrinolytic activity can still 
be present even in patients with good glycemic 
control. This is supported by a study showing that 
coagulation and fibrinolytic abnormalities has a 
strong association with the presence of diabetic 
vascular complications and the association was 
stronger than the degree of glycemia.24
CONCLUSION
Median vitreous AGEs levels are significantly 
higher in patients with uncontrolled than those 
with controlled hyperglycemia. Blood HbA1c 
levels can be used to assess vitreous AGEs level 
by the following calculation: vitreous AGEs = 
-1.442+(1.740 x HbA1c).  Blood HbA1c level 
can not be used to predict vitreous D-dimer level.
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